Compare Stocks: SLN, BEAM, IRON, and IMNM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$24.52 +1.2%	$26.75	$20.23 ▼ $38.26	$2.50B	2.22	1.89 million shs	1.64 million shs
IMNM Immunome	$21.89 +1.0%	$25.42	$11.09 ▼ $30.06	$2.46B	2.13	1.24 million shs	916,987 shs
IRON Disc Medicine	$65.87 +1.5%	$75.60	$40.00 ▼ $99.50	$248.94M	0.97	513,380 shs	784,081 shs
SLN Silence Therapeutics	$10.80 -3.6%	$12.79	$4.19 ▼ $17.58	$650.26M	1.45	794,738 shs	884,414 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+1.20%	-5.44%	-16.37%	-26.76%	+2.55%
IMNM Immunome	+0.97%	-14.99%	-20.60%	+1.86%	+93.03%
IRON Disc Medicine	+1.46%	-3.81%	-17.69%	-12.11%	+1.25%
SLN Silence Therapeutics	-3.57%	-12.12%	-19.52%	+2.86%	+90.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$24.52 +1.2%	$26.75	$20.23 ▼ $38.26	$2.50B	2.22	1.89 million shs	1.64 million shs
IMNM Immunome	$21.89 +1.0%	$25.42	$11.09 ▼ $30.06	$2.46B	2.13	1.24 million shs	916,987 shs
IRON Disc Medicine	$65.87 +1.5%	$75.60	$40.00 ▼ $99.50	$248.94M	0.97	513,380 shs	784,081 shs
SLN Silence Therapeutics	$10.80 -3.6%	$12.79	$4.19 ▼ $17.58	$650.26M	1.45	794,738 shs	884,414 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+1.20%	-5.44%	-16.37%	-26.76%	+2.55%
IMNM Immunome	+0.97%	-14.99%	-20.60%	+1.86%	+93.03%
IRON Disc Medicine	+1.46%	-3.81%	-17.69%	-12.11%	+1.25%
SLN Silence Therapeutics	-3.57%	-12.12%	-19.52%	+2.86%	+90.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.79	Moderate Buy	$49.00	99.84% Upside
IMNM Immunome	2.85	Moderate Buy	$35.18	60.72% Upside
IRON Disc Medicine	2.77	Moderate Buy	$110.18	67.27% Upside
SLN Silence Therapeutics	2.83	Moderate Buy	$53.50	395.37% Upside

Current Analyst Ratings Breakdown

Latest SLN, BEAM, IRON, and IMNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	BEAM Beam Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/21/2026	IMNM Immunome	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$32.00
9/16/2026	IRON Disc Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$79.00 ➝ $86.00
9/10/2026	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/10/2026	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/10/2026	IRON Disc Medicine	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$128.00
9/10/2026	IMNM Immunome	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/10/2026	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$100.00
9/9/2026	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
9/2/2026	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$88.00 ➝ $100.00
9/1/2026	IRON Disc Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight

(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$156.04M	16.23	N/A	N/A	$12.20 per share	2.01
IMNM Immunome	N/A	N/A	N/A	N/A	$5.75 per share	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	$19.52 per share	N/A
SLN Silence Therapeutics	$615K	1,057.33	N/A	N/A	$1.32 per share	8.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
IRON Disc Medicine	-$212.18M	-$6.58	N/A	N/A	N/A	N/A	-37.17%	-33.65%	11/5/2026 (Estimated)
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-106.94%	-47.99%	11/5/2026 (Estimated)

Latest SLN, BEAM, IRON, and IMNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	N/A
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
7/30/2026	Q2 2026	IRON Disc Medicine	-$1.71	-$1.54	+$0.17	-$1.54	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.67%	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
IMNM Immunome	N/A	15.08	15.08
IRON Disc Medicine	0.09	24.14	24.14
SLN Silence Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
IMNM Immunome	44.58%
IRON Disc Medicine	83.70%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
IMNM Immunome	7.21%
IRON Disc Medicine	3.76%
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	540	103.29 million	99.36 million	Optionable
IMNM Immunome	177	113.58 million	105.39 million	Optionable
IRON Disc Medicine	165	3.83 million	36.95 million	Not Optionable
SLN Silence Therapeutics	88	60.21 million	58.40 million	Not Optionable

SLN, BEAM, IRON, and IMNM Headlines

Recent News About These Companies

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Stock Has Average Target Price of $53.50 According to Analysts

4 hours ago | americanbankingnews.com

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Rating of "Moderate Buy" from Analysts

September 25, 2026 | marketbeat.com

Head to Head Review: Silence Therapeutics (NASDAQ:SLN) versus Ultragenyx Pharmaceutical (NASDAQ:RARE)

September 24, 2026 | americanbankingnews.com

Silence Therapeutics (NASDAQ:SLN) Shares Down 8.7% - Time to Sell?

September 23, 2026 | marketbeat.com

Contrasting Absci (NASDAQ:ABSI) & Silence Therapeutics (NASDAQ:SLN)

September 21, 2026 | americanbankingnews.com

Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Stock Price Down 5.4% - Here's Why

September 15, 2026 | marketbeat.com

Seven Fleet Capital Management LP Sells 96,652 Shares of Silence Therapeutics PLC Sponsored ADR $SLN

September 5, 2026 | marketbeat.com

Silence Therapeutics to Participate in Three September Investor Conferences

September 2, 2026 | cityam.com

Silence Therapeutics (NASDAQ:SLN) Stock Price Up 5.8% - Should You Buy?

September 1, 2026 | marketbeat.com

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 31, 2026 | marketbeat.com

Silence Therapeutics: Making Some Recent Noise

August 19, 2026 | seekingalpha.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

August 14, 2026 | businesswire.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

August 14, 2026 | cityam.com

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

August 13, 2026 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

August 12, 2026 | theglobeandmail.com

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

August 11, 2026 | businesswire.com

Morgan Stanley maintains Overweight rating on Silence Therapeutics

August 11, 2026 | seekingalpha.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow

August 11, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SLN, BEAM, IRON, and IMNM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$24.52 +0.29 (+1.20%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$24.28 -0.23 (-0.96%)

As of 08:10 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Immunome NASDAQ:IMNM

$21.89 +0.21 (+0.97%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$22.14 +0.25 (+1.16%)

As of 07:48 AM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Disc Medicine NASDAQ:IRON

$65.87 +0.95 (+1.46%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$66.54 +0.66 (+1.01%)

As of 07:39 AM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Silence Therapeutics NASDAQ:SLN

$10.80 -0.40 (-3.57%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$10.85 +0.05 (+0.45%)

As of 08:09 AM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLN, BEAM, IRON, and IMNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLN, BEAM, IRON, and IMNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLN, BEAM, IRON, and IMNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLN, BEAM, IRON, and IMNM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Immunome NASDAQ:IMNM

Disc Medicine NASDAQ:IRON

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLN, BEAM, IRON, and IMNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLN, BEAM, IRON, and IMNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLN, BEAM, IRON, and IMNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLN, BEAM, IRON, and IMNM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Immunome NASDAQ:IMNM

Disc Medicine NASDAQ:IRON

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools